ASPARGO
Aspargo Labs develops patient-focused solutions and must-have medicines by utilizing our proprietary technology to enhance previously approved drugs with well-known pharmacology profiles.
Our initial product candidate is a proprietary oral suspension formulation of sildenafil citrate, the active ingredient in VIAGRA®.
Aspargo’s unique oral spray formulation is designed to offer patients an alternative to tablet medications, such as VIAGRA® and Cialis® and their respective generic equivalents.
Aspargo’s oral spray suspension formulation of sildenafil citrate, the active ingredient in VIAGRA®, is a novel and convenient route of administration for this commonly prescribed medication for erectile dysfunction.
Metered pump delivers exactly 12.5 mg per push of the pump to facilitate appropriate dose titration based on patient needs.
Convenient administration, accurate dosing, faster onset, and retains effectiveness following ingestion of food or drink.
Aspargo’s proprietary Sildenafil Oral Spray is intended to satisfy the unmet need for an easy to administer dosage form of sildenafil citrate for use in multiple indications.
Aspargo Labs owns the exclusive commercialization rights to Sildenafil Oral Spray in the United States and more than 75 countries throughout Europe, Asia, the Middle East, South America, the United Kingdom and Canada under a patent licensing agreement with Farmalíder S.A. (Madrid, Spain), Market Exclusivity and IP Protection.
INVESTOR NEWS
To find out more about Aspargo Labs, send us a message.